Study to Evaluate Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors

Study Title

A Study to Evaluate 5 ־¼g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

Teva Identifier

XM02-ONC-201 | 2014-001772-55

ClinicalTrials.gov Identifier

NCT02190721

Study Status

Completed

Trial Condition(s)

Neutropenia

Interventions

Drug: tbo-filgrastim

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

1 Month to 16 Years

Trial Duration

May 12, 2015 - April 4, 2017

Phase

Phase 2

Study Type

Interventional